A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients

BACKGROUND: Amuvatinib (MP-470) is a multi-targeted kinase inhibitor with potent activity against c-Kit, synergistic with DNA-damaging agents. We evaluated amuvatinib in combination with platinum-etoposide (EP) chemotherapy by objective response rate, survival, and tolerability in platinum-refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Byers, Lauren Averett, Horn, Leora, Ghandi, Jitendra, Kloecker, Goetz, Owonikoko, Taofeek, Waqar, Saiama Naheed, Krzakowski, Maciej, Cardnell, Robert J., Fujimoto, Junya, Taverna, Pietro, Azab, Mohammad, Camidge, David Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655298/
https://www.ncbi.nlm.nih.gov/pubmed/29113403
http://dx.doi.org/10.18632/oncotarget.19888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655298/
https://www.ncbi.nlm.nih.gov/pubmed/29113403
http://dx.doi.org/10.18632/oncotarget.19888

Ejemplares similares